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Abstract
The solid dispersion has become a momentous solubilization technology for poorly water
soluble drugs.It is usually two component system of drug polymer, which interacts between
the drug design and its performance. Solid dispersion in water-soluble carriers have
interacted a means of developing the dissolution rate and bioavailability of the hydrophobic
drugs. The aim of this present study is to compare the solubility of different drugs with the
increased polymer concentration. The solid dispersion is stable under accelerated storage
conditions.PVP K30 brings out a way to enhance the solubility and dissolution rate of the
certain drug. Solid dispersions have attracted considerable interest as an important means of
mounting dissolution rate with various methodologies. The main focus of this article is on
advantages, disadvantages, developing various methods and categorization of the solid
dispersion. There are various carriers which have been used in the solid dispersion
technology and this has been focused in this article.
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Chapter-1
INTRODUCTION
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1. Introduction:
An amount of methodologies can be adapted to progress solubility and bioavailability of
poorly soluble drugs. The procedure is worn for the solubilization of drug includes solid
dispersion, micronization, chemical modification, PH adjustment,complexation,co-
solvency,micellersolubilisation,hydrotrophy etc. The idiom solubility is defined as greatest
quantity of solute dissolved in the solvent. It can be two types. 1. Qualitative or
2.Quantitative.(Sato et al,1981)Absorption of drugs from gastrointestinal tract is limited by
various factors. The most noteworthy contributors being poor aqueous solubility and poor
membrane permeability of the drug molecule. When the drug is delivered orally, it must first
dissolve in the gastric/intestinal fluid. Consequently the drug with the poor solubility will
typically show dissolution rate limited absorption. Solid dispersion technology is used to
improve the characteristics of poorly water soluble drugs and oral bioavailability. Different
solid dispersion system has been established in the pharmaceutical journalism to progress the
dissolution properties of poorly water soluble drugs. It has been anticipated that 40% of new
chemical entities presently being revealed are poorly water soluble. (Sekigushi and
Obi,1961)) Various strategies have been developed to overcome these problems. These are
prodrug formation, complexation, microcapsulation, the use of surfactants, lipids,permeation
enhancers,micronization,saltformation,cyclodextrins,nanoparticles,solid dispersion and self
emulsifying drug delivery system.(Okamoto and Oguni,1996)The therapeutic response of a
drug normally dependent on the adequate concentration of the drug that are achieved and
maintained at the site or site of action of the drug. The majority of the drug that is
administered orally is intended to be absorbed from the gastrointestinal tract. The rate
limiting step may vary from drug to drug (Jain et al,2006). The enhancement of oral
bioavailability of these poorly water soluble drugs remains one of the most challenging
aspects in the drug development. The biopharmaceutical classification system divides into
four classes that is depending on the in vivo permeability data and the in vitro solubility.
Among these classes number II class shows the poor solubility and high permeability. Class
II drugs low the ability to dissolve and it is the more important limitation to their overall rate
and extent the absorption.(Simonelli andMehta,1969) Then their ability to permeate through
the membrane. class II enhance the  aqueous solubility or dissolution rate. There are various
strategies to improve the dissolution rate and the aqueous solubility. These are solid
dispersion, particle size reduction, salt formation, complexation with cyclodextrin, The use of
co solvents and self emulsifying agents. Among these all techniques solid dispersion has
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proven to be very successful.The dissolution rate of the poorly water soluble drug in a solid
dispersion is increased by i)increasing the surface area and ii)improving wettability hence
decreasing the thickness of the diffusion layer iii)enhancing the solubility of the drug by the
formation of the supersaturated solution.(Amidon et al,1995)
Table 1: Parts of solvent required for one part of solute
Definition Parts of solvent required for one part of solute
Very soluble <1
Freely soluble 1-10
Soluble 10-30
Sparingly soluble 30-100
Slightly soluble 100-1000
Very slightly soluble 1000-10,000
Insoluble 10,000
The therapeutic action of drug depends on the bioavailability of drug and it is depends on the
solubility of the drug .The drug must be present for the absorption in the absoption site for
aqueous state.For the oral bioavailability of the drug ,it is a decisive step to release the
drug.poorly soluble drugs with low gastrointestinal solubility and high permeability and the
drugs with low solubility and permeability examine the problem of oral solubility and thus
increase the bioavailability.(Chiou and Riegelman,1971)
Table 2 : List of some poor water soluble drugs, category and solubility
profile
Drugs Category Solubility profile
Ibuprofen Anti inflammatory drug ibuprofen is soluble in Water. Less
than 1mg of
Ibuprofen dissolves in 1 ml of
Water
Furosemide Diuretics It is more soluble in alcohol/water
Mixtures
Gliclazide Anti diabetic Soluble in acetone, sparingly
soluble
Glipizide Anti diabetic Ethanol(95%),slightly soluble in
Dichloromethane, slightly soluble
In ethanol  95%
Aceclofenac Anti inflammatory analgesic partially insoluble in water;
Freely soluble  in acetone,
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Soluble in ethanol 95%
Indomethacin Anti inflammatory analgesic soluble in chloroform,sparingly
Soluble  in ethanol  95%
Ketoprofen Anti inflammatory analgesic Freely soluble in ethanol 95%,
Chloroform and ether
Diclofenac Anti inflammatory freely soluble in methanol,
Soluble  in ethanol,
Sparingly soluble in water
Felodipine Calcium channel blocker sparingly soluble in
Dichloromethane
,slightly soluble in water
Loperamide antidiarrheals soluble in acetone, sparingly
Soluble in ethanol  95%
Morphine NSAID soluble in water,freely
Soluble in hot water ,more
Soluble in ethanol.
Naproxen anti inflammatory soluble in water,freely
Soluble in hot wate and
More soluble in ethanol
Nimodipine calcium channel blocker poor water soluble drug
Ofloxacin antibiotic soluble in ethanol and
Chloroform,insoluble in
Ether
1.1. Mechanism of solubilization:
Solubility is defined as the maximum concentration of the drug solute that are dissolved in
the solvent under the specified temperature,PH, and pressure.the drug solubility is related to
the rate  of bioavailability.
The solubility of a weak acid or weak base varies with the fraction of PH.
Solubility of weak acid,total solubility(Cs)is given by-
Cs=[HA]+[A-]
Where [HA]=intrinsic solubility of non ionized acid
[A-]=the concentration of its anion.
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The anion concentration can be expressed in terms of dissociation constant Ka
Cs=Co+Ka[Co/h=]
Where Co=non ionixed acid concentration
This indicates that the solubility of the weak acid increases with increase in the ph solubility
is optimal at higher Ph.
Solubility of a weak base is given by the expression:
Cs=Co+[H+/Ka]
It indicates that the solubility of the weak base decreases with increasing PH and the
solubility is optimal at the lower ph.(Ford,1986)
1.2. Various approaches for solubility enhancement:
1. Drug dispersion in carries:
-Eutectic mixtures
-Solid solutions
-Solid dispersion
2. Solubilization with solvent
3. Complexation with polymer
4. Micronization
5. Alteration in PH
6. Use of surfactant
7. Use of cyclodextrin
8. Change in physical form
9. Use of prodrug and drug derivatization
P a g e 6 | 6
1.3. Definition of Solid dispersion:
Chiou and Riegelman defined solid dispersion as “a dispersion involving the formation of
eutectic mixture of drugs with water soluble carries by melting of their physical
mixtures”(Chiou and riegleman,1986).The term solid dispersion refers to the dispersion of
one or more active ingredient in an inert carrier or matrix at solid solid state prepared by
melting(fusion),solvent, or the melting solvent method. Once the solid dispersion was
exposed to aqueous media and the carrier dissolved, the drug is released as very fine,
colloidal particles. the term solid dispersion refers to the group of solid products consisting of
at least two different components, generally a hydrophobic drug and hydrophilic
matrix.(Lidenberg,2004) The matrix can be either crystalline or amorphous. The dispersion of
a drug or drugs in a solid diluents or diluents by traditional mechanical mixing is not included
in this category. Therefore, based on their molecular arrangements, different types of solid
dispersions can be distinguished and combination can be encountered in the same sample i.e
some molecules are present in clusters while some are molecularly dispersed. In various
studies the type of solid dispersion is based on the method of preparation. Since different
Chemical modification
Prodrug
salt formation
Physical modification
Nanocrystals
Co-crystals
Solid distersions
Poorly water soluble drugs
Alteration of solvent
pH adjustment
Co-solvents
Wetting Agents
Carrier system
Cyclodextrin
micelles
Microemulsion
P a g e 7 | 7
preparation methods can result in different subtypes ,it can be argue that solid dispersions
should preferably designated according to their molecular arrangement. So ,the solid
dispersion refers to the group of solid products consisting of at least two different
components generally a hydrophilic matrix and a hydrophobic drug.(Yal et al,1985)
1.4. Classification of solid dispersion:
1. Simple eutectic mixture
2. Solid solution
3. Glass solution
4. Complex formation
5. Amorphous precipitation in a crystalline carrier
1.4.1. Simple eutectic mixture:
It can be described as an intimately blended physical mixture of two crystalline components,
which are completely miscible in the liquid state, but not in the solid state.
Fig 1 : phase diagram for eutectic system(Boral,1995)
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1.4.2. Solid solutions:
It is consist of a solid solute dissolved in a solid solvent.The particle size is reduced to
molecular level.it was reported that the solid solution of a poorly soluble drug in a fast
dissolving carrier achieves a faster dissolution rate than a eutectic mixture because the drug
particle size is reduced to its absolute minimum as it is molecularly dispersed in the carrier in
a solid solution.The effective surface area is significantly higher hence the dissolution rate is
increased.Solid solutions classified by their miscibility characteristics.(Mallet et al,1965)
1. Continuous solid solutions:
In a continuous solid solutions the components are totally miscible with one another in all
proportions in both solid and the liquid state. The lattice energy of the continuous solid
solution at all compositions is higher than that of the respective pure components in the solid
state, because the heteromolecular bonding is higher than the homomolecular.(Boral,1995)
Fig 2 : Hypothetical  phase diagram of a continuous solid solution
(Jain and shakrma,2006)
2. Discontinuous solid solution:
In discontinuous solid solution the miscibility or solubility of one component in the other is
limited. Formulation of dosage form with solid solution will depend on both the mutual
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solubilities of the two components and dose of the drug component. The maximum limit of a
tablet or capsule is about 1 gram. Assuming that the solubility of the drug in the carrier is
10%,doses of above 100 mg would not be feasible with its strategy. If the drug solubility in
the carrier is significantly higher than 10%,larger doses can be entertained.(Jain and Sharma
2006)
Fig 3 : Hypothetical phase diagram of a discontinuous solid solution
(Bulter and Mattewk,1999)
3. Substitutional solid solution:
Here the solid molecules replace the solvent molecule in the crystal lattice of the solid
solvent. An extensive solid solution can only be formed when the effective diameter of the
solute differs by less than 15% from that of thesolvent and when the packing patterns of
solvent and solute are comparable.
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Figure 4:Substitutional solid solution (Bulter and Mattew,1999)
3. Interstitial solid solution:
In the interstitial solid solutions the dissolved molecules occupy the interstitial spaces
between the solvent molecules in the solvent crystal lattice. The diameter of the solute
molecules should be less than 59% of the diameter of the solventmolecules. The volume of
the solute molecules should be less than 20% of that of the solvent.(Graham et al,1966)
Figure 5: Intestinal solid solution
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4. Amorphous solid solutions:
The solute molecules are dispersed molecularly but irregularly within the amorphous solvent.
Various carrier were used included urea, sucrose, dextrose, galactose, polyvinyl pyrrolidone
and polyethylene glycol.
Figure 6 : Amorphous solid solution (Buech,2007)
1.4.3. Glass solutions:
It is also known as an amorphous solution,is a homogenous system in which a glassy or a
vitreous form of carrier solubilities drug molecules. The glassy or vitreous state is
characterized by transparency and brittleness below the glass transition temperature. The
temperature at which the glassy polymer becomes rubbery on heating and a rubbery polymer
reverts to a glassy one on cooling is called the glass transition temperature, Tg.(Mullins and
Macek,1960) Well below the Tg, the glass solutions are hard, stiff glassy materials; at the
temperature well above Tg, the materials are rubbery. They are formed by either cooling of
the melt or evaporation of a solution. Upon cooling or evaporation ,the drug is vitrified into
its glassy state in the amorphous carrier. Specific volume, specific heat, viscosity, refractive
index, compressibility, thermal conductivity and other physico chemical properties of the
glass show changes when cooled or heated through the glass transition temperature.
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Figure 7 : Variation of enthalpy with temperature (Buech,2007)
1.4.4. Complex formation:
Here the drug forms  a complex with an inert water soluble carrier in the solid state. The
availability of the drug depends on the stability constant of the complex and the absorption
rate of the drug. It also depends on the solubility of the drug.Herecyclo dextrins are mostly
used. This is linked with the oligosaccharides of alpha –D-glucopyranose containing a
relatively hydrophobic central cavity and hydrophilic outer surface. The drugs that are poorly
water soluble, Their solubility can be increased by this process.
1.4.5. Amorphous precipitation in a crystalline carrier:
The drug also may precipitate in the amorphous form in the crystalline carrier.Here the
energy state is high and this high energy state of the drug generally produces the greater
dissolution rate than the corresponding crystalline forms of the drug.(Gines et al,1995)
1.5. Advantages of solid dispersion:
By using solid dispersion ,management of the drug release profile is achieved by
manipulation of the carrier and solid dispersion particles properties. The parameters are-drug
P a g e 13 | 13
crystallinity, particle porosity, molecular weight and composition and wettability, when it is
controlled successfully the bioavailability is improved.
 particles with reduced particle size:
Particle sizes of the particles are reduced during the preparation of the solid dispersion
and the surface area is improved. As a result it increases the dissolution rate. However
bioavailability is improved.
 particles with improved wettability:
During the preparation of solid dispersion, the wettability is improved.Many carriers
are used for the solid dispersion to enhance the wetting properties.So improved
wetting may lead to reduced agglomeration and increased surface area.
 particles with higher porosity
Highly degree of porosity have been found in the particles of solid dispersion.The
increase in porosity depend on the carrier properties.solid dispersion that contains
linear polymer result in a higher dissolution rate. This increased in porosity hastens
the drug release profile.
 drugs in amorphous state:
Drugs in amorphous state shows higher release of drug because there is no any energy
to break the crystal lattice during the dissolution process.In solid dispersion,drugs are
presented as supersaturated  solutions.It forms  the higher solubility if it is in the
metastable polymorphic form.(Butler and Mattew,1999)
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1.6. Disadvantages of solid dispersion:
 Solid dispersion are not broadly used in the commercial products because
duringprocessing or storage there is the possibility to undergo the crystallization from
the amorphous state.
 Moisture has the great effect on the storage stability of the amorphous
pharmaceuticals because it may increase drug mobility and promote drug
crystallization.
 Polymers that are used in the solid dispersion can absorb moisture.And this result in
the phase separation,crystal growth or conversion from the amorphous to the
crystalline state.This may result in decreased solubility and dissolution rate.
 For the purpose of manufacturing there is poor scale up.
 Expensive method.
 Difficult to incorporate into formulation of dosage forms.
 Scale-up of manufacturing process.
 Stability of the drug and vechicle.
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1.7.Pharmaceutical applications of solid dispersion:
 To increase the solubility of the poorly soluble drugs that increases the dissolution
rate, bioavailability and the absorption.
 To obtain the homogeneous distribution of drugs in solid state.
 To protect against the decomposition and stabilize the unstable drugs by different
process such as oxidation, hydrolysis, racemization, photo oxidation etc.
 To dispense liquid or gaseous compounds.
 To reduce the side effects of drugs.
 To formulate the sustained release preparation of soluble drugs by dispersing the
poorly soluble or insoluble carrier.
 To formulate the fast release priming drug.
 To mask the unpleasant smell, odor.
 To avoid undesirable incompatibilities.
 To reduce pre systemic inactivation of drugs like morphine.
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Chapter-2
MATERIALS AND METHODS
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2.1. Preparation of solid dispersion:
Figure 8: Preparation of solid dispersion
Many techniques are now used for the preparation of the solid dispersion.But phase
separation and demixing are the most common problem in the preparation of solid
dispersion.It was reported that that the cooling process in the rapid way reduce the extent of
phase separation .The techniques are-
2.1.1. Solvent evaporation method:
In this method there are two important steps:
The solution containing the matrix and the drug is prepared by proper molecular level mixing
with the solvent.
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2.1.2.Removal of the solvent:
The aim of this method is to dissolve the drug and the carrier.This should be done
simultaneously in a common solvent,this is characterized by the removal of solvent by
evaporation.Thetemperature is usually-23-65oc.The solvent also can be removed by the
freeze drying or spray drying.The drug that are used in the solid dispersion are normally
hydrophobic and the carrier is hydrophilic.Sometimes it becomes difficult to identify a
common solvent to dissolve both components.(Martin et al,2003)
2.1.3. Hot melt extrusion method:
This method was introduced in 1970s as the manufacturing tool in the pharmaceutical
industry.The basic principle of this technology is similar to the fusion method except for the
employing of extruder for high shear mixing.This method is very common in the processing
plastics in the polymer industry.This has been useful in the preparation of solid dispersion in
the single step.(Sekiguchi and Obi,1961) It is also very important for the preparation of
various dosage forms in the pharmaceutical industry such as preparation of sustained release
pellets.To form solid dispersion of various drugs  during hot melt extrusion,polymers such as
PVP,HPMC acetate succinate etc were used.
Table 3 : List of drugs and polymers used during the preparation:
Drug
Carrier
Dosage form
Oxprenolol   hydrochloride eudragitrs/RL pellets
Lidocaine Eudragit E
transdermal drug delivery
Diltiazem hydrochloride Eudragit S
granules
Theophyllin Eudragit 4135
pellets
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2.1.4. Supercritical fluid technology:
This technology was introduced in the late 1980s and early 1990s.It is any substance at a
temperature and pressure above its critical point.It can diffuse through the solids like a gas
and like a liquid dissolve the materials.If the critical point is close to it,there is small changes
in the temperature and the pressure and this result large changes in density.(Mura et al,1996)
Figure 9 : Supercritical region of a hypothetical compound
Supercritical fluid technology is suitable as a substitute for organic solvents in a range of
laboratory processes and industry. Depending on the method different applications have been
introduced. these are-
Precipitation from supercritical solutions-rapid expansion of supercritical solution(RESS)
Gas antisolvent or supercritical antisolvent(SAS) recrystallization
Solution enhanced dispersion by supercritical fluids(SEDS)
Aerosol solvent interaction system
Precipitation with compressed antisolvent(OCA)
Presipitation from gas saturated solutions(PGSS)
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2.1.4. Direct capsule filling:
Francois and Jones was first described this method.They described that filling of semisolid
materials into hard gelatin capsules as melts,which occur in the room temperature.For this
reason Chathan prepared PEG-based solid dispersion by filling the PEG melt in the hard
gelatin capsule.Then the molten dispersion was cooled to the room temperature.But PEG is
not the suitable carrier for the direct capsule filling because the water soluble carrier
dissolved more rapidly than the drug.As a result rich layer was formed on the surface which
prevent further dissolution of drug.(Sharma and Joshi,2007)
2.1.5. Use of surfactants:
Use if surfactant for solid dispersion has been increased in these recent years.Serajuddin
achieved a complete dissolution of drug from solid dispersion by using surface active or
surface emulsifying carriers.These carriers prevent the formation of water  insoluble surface
layers by dispersing which resulted in a high surface of the drug.This facilitate the
gastrointestinal fluids in the presence of bile salt,lecithin.
The commonly used surface active agents are-gelucire44/14,vitamin E TPGS NF and Tween
80.(Zerrouk et al,2001)
2.1.6. Electrostatic spinning:
In this process a drug matrix solution is pumped through an orifice and that is then used for
the electrical field.when electrical forces overcome the surface tension of the drug then fibers
of submicron diameters are formed.When the solvents evaporate then the fibers are
collected.Thiselectrospunfibres are incorporated into hard gelatin capsule.The diameter of the
fiber can be adjusted by surface tension,electrical field and dielectric constant.After rapid
evaporation of the fiber,these fibers are used for the further process.(Wang et al,2005)
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2.1.7. Melt agglomeration:
A processor  has been used for the preparation of solid dispersion by this melt agglomeration
method and this processor  is rotary processor.In this process binder acts as the carrier.Solid
dispersion are prepared by either heating binder,drug and excipient to a temperature above
the melting point of the binder.Molten binder are heated excipient by using high shear
mixing.(okonogi,2006) It has been reported that the melt in procedure gives a higher
dissolution rate.Melt in procedure also results in homogenous distribution of drug in
agglomerate.(Nokhodchi,2007)
2.1.8.Cryogenic technique:
It is reported that all the fuids have a critical temperature which lies below or within the
normal ambient temperature range and this is defined as cryogenic.The upper limit of the
normal ambient range is 323.18 degree Kelvin.Based on this concept,cryogen are gases that
can not exist as liquid,withoutrefrigeration.In the family of cryogens it begins with Hillium II
near the lower boundary and carbon di oxide is included.This techniques has developed to
enhance the dissolution rate by creating nonstructured amorphous particles with high degree
of porosity.There are various cryogenic technique for the preparation of solid dispersion
particles.Theseares-
Spray freezing onto cryogenic fluids
Spray freezing into cryogenic fluids
Spray freeze drying
Ultra rapid freezing
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Table 4: List of some of the solid dispersion of poorly water soluble drugs
prepared by different methods:
Drug Polymer Method
Fenofibrate PEG6000 Melt evaporation,
Chloroform
Poloxamer407 Lyophillization
Glipizid PEG6000, Fusion (melt) method,
Dichloromethane
Mannitol PVP30 Solvent evaporation method
Acyclovir PEG6000,PVP30 Solvent evaporation method
Methanol
Valdecoxib PVP Kneading
Water
Flubiprofen HPC Solvent evaporation method
Ethanol
Efavirenz PEG6000 Solvent evaporation method
Acetone
Chlordiazepoxide PVP30,Mannitol Co-precipitation method
Ethanol
Itraconazole Eudragit Melt method
Furosemide Sodium starch glycolate kneading method
Water:ethanol
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2.2. Characterization of solid dispersion:
2.2.1. Thermal analysis:
This is used for the study of the physicochemical interaction of two or more
component system.
2.2.2. Cooling curve method:
Until a homogenous melt are obtained the physical mixtures of various compositions are
heated. The temperature is recorded. There are many disadvantages in this method .it is time
consuming ,it requires large amount of solvent, changes in slopes can be missed. it occurs if
the cooling is done very rapidly. Another is this method can not be applied to samples that
decompose after melting. This is very difficult to detect the samples when there is small solid
solid solubility. This method is recently used for the determination of phase diagrams of
deoxycholic acid menadione.(Guillory et al,1969)
2.2.3. Thaw-melt method:
A capillary melting tube is taken and that is filled with a sample of solidified mixture.Then it
is heated gradually. Thaw point is referred to the temperature on crossing a solidus line.A
stirring device in a capillary tube gives the more accurate results.(Moore,1969) This stirring
facilitates the homogenous system and this only affect on the melting point but not in the
thaw point.In the comparison of the simple eutectic system and the limited solid
solution,there is a diagnostic line in the thaw point. There is no need to use complicated
device.(Sekiguchi and Obi,1964)
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2.2.4. Thermo microscopic method:
To study the phase diagram of binary system ,a hot stage of polarized microscopy was
used.The physical mixture is placed on the slide cover with a cover slip this is sealed .For the
sealing silicone grease is used which prevent the sublimation. Until the mixture is liquefies,
the mixture is heated. After cooling the mixture is again heated for 4 mins .By the visual
observation then the thaw and the melting point are then determined. The main advantage of
this method is, it is simple and it requires less sample.(R.E, 1964) But there are some
disadvantages too.It suffers from being subjective, limited to thermally stable compounds and
potentially inhomogeneous in distribution after resolidification.
2.2.5. DTA:
For studying the phase equilibria of either a pure compound or a mixture DTA is an effective
thermal method .it is associated with physical or chemical changes. The temperature or time
is recorded automatically as the substance is heated at a uniform time. polymorphic,
transitions, evaporations, sublimation desolvation and other types of decomposition can be
detected by this DTA (Wendlandt,1964).The main advantage of this method is in
constructing phase diagrams of high reproducibility. Although there are some sensitivity and
accuracy of the DTA like sample size, heatingrate, sample geometry, thermal conductivity etc
but these variables can be optimize the desired characteristics of the DTA apparatus. This is
especially a valuable method for detecting the presence of small amount of eutectic in the
mixture (Sekiguchi et al,1964)
2.2.6. Zone melting method:
In 1952 this technique was first introduced (Pfann,1966).It is primarily used for the
ultrapurification of metals and inorganic and organic compounds.For metal and organic and
inorganic compounds the phase diagram can be detected.For the mixing of the liquid in the
melting zone a mechanical stirring device is also required.The bar is sectioned and analyzed
for its chemical composition,after the zone melting is finished.Aphase diagram of binary or
multicomponent system can be constructed from the temperature and chemical composition.
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This method is limited to the compounds that have high thermal solubility and low volatility
(Pfann,1966).It is important for the determination of exact chemical composition of a eutectic
and the minute solid- solid solubility.By this method many phase diagrams has been detected.
2.2.7. X-ray diffraction method:
This method is used to measure the intensity of the Xray diffraction from different
angle.There are both the advantages and the disadvantages of this method. A better resolution
of diffraction peaks can be obtained in the former method.It is easy to determine the relative
diffraction intensity.on the other side,it requires more sample and less realibility (Wald and
Rosenberg,1965) It is also more sensitive to sample preparation and position.For studying the
physical nature of solid dispersion this method is more important.It is also used for the study
of binary eutectic tool of chloramphenicol-urea griseofulvin succinic acid.Many phase
diagrams of inorganic and metal compounds can be detected by this method. Diffraction
peaks of each crystalline components can be found in diffraction spectra are obtained from
the simple eutectic system.(Mallet and Mullet,1965)
2.2.8. Microscopic method:
Microscopic method is used in the study of polymorphism and in the morphology of solid
dispersion. By the polarizing microscope ,the fine particles of crystallization in the glass
polyvinyl pyrrolidone matrix can be detected. For this process a high resolution of an electron
microscope was used. The limitation of this technique is ,it is not suitable for the chemicals
with high atomic numbers.
2.2.9. Spectroscopic method:
Visible absorption spectroscopy is used to measure the low concentration of beta carotene.It
is used in polyvinyl pyrrolidone.It is dissolved in organic solvents but the beta particles are
not dissolved.This indicates that beta carotene is dispersed molecularly in the polymer.IR
spectroscopy is also used in the study of solid solution of nitrile ion in many inorganic
compounds such as KBR,nacl etc.(Moore,1964)
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2.2.10. Dissolution rate method:
It is the recent method which is proposed by Allen and Kwan.This method is developed to
study the degree of crystallinity which is mainly in solid-solid equilibria,especially in
temperature regions below solid-liquid equilibria.The methods involve in vitro method
(Kakumanu and Bansal,2003) .The technique is simple to perform,except some binary
system. In the binary system the tablet surface may not be remain constant.
2.2.11. Thermodynamic method:
By this parameter the phase diagram of eutectic and solid solutions system can be
constructed.Also the solubility gap of agbr-nabr system was found from the thermodynamic
data that is obtained from the electromotive force study by galvanic cell.(Rastogi,1956)
2.2.12. Aging of solid dispersion:
The solid dispersion act as the potential dosage form of medication for increasing dissolution
and absorption rates of poorly soluble drugs.However this results the aging or storage under
various conditions and it effects the fast release characteristics and chemical stabilities,that
have not been reported (Ahmed,1993).The interesting and important research of this method
is feasible.There are many effects on non pharmaceuticals systems also.This method has
effect on dissolution  andbropirimine whereas such ageing has no effect on the dissolution of
drug.(Chiou and Riegelman,1971)
2.2.13. Aging effects of eutectic mixture:
As we know that the dispersed phase particles tend to the coarsen on aging.This is because
the interfacial energy of the system is reduced by the concomitant reduction in interface
area.This system is occurred in eutectic system with or without solid solution formation. The
extent increases with the time and the aging temperature.(Rastogi and Bassi,1964)
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2.2.14. Aging effect on glass solution:
As we know that glass solution is a metastable form and it is subjected to the aging
transformation,forming a more stable form.This process is occur more rapidly or extremely
slowly because of the untreated ordinary window glass kept at the room temperature.Small
angle Xray scattering and electrone microscope methods were used to study the kinetics
.(Mallet and Fay,1965)
2.2.15. Aging effects of solid solution:
There is the most important aging effect from the solid solutions is the precipitation from the
solid solutions that is supersaturated along with the physical and the chemical
properties.There are some hardening effect and those are time,temperature  and the function
of composition.The preparation of aging for the long time at a given temperature may also
cause them to lose their hardness. (Smoluchowski,1951)
2.3. Suitable properties of a carrier for solid dispersions:
When to choose a carrier following criteria should be considered:
1. High water solubility-to improve wet ability and enhance dissolution
2. High glass transition point-improve stability
3.Minimal water uptake
4. Soluble in common solvent with drug-solvent evaporation
5. Relatively low melting point-melting process
6.Capable of forming a solid solution with the drug-similar solubility parameters
2.3.1. First generation carriers:
Crystalline carriers:Urea, Sugars, Organic acids
2.3.2. Second generation carriers:
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Amorphous carriers:
Polyethyleneglycol,povidone,polyvinylacetate,polymethacrylate,cellulose derivatives
2.3.3. Third generation carriers:
Tween 80, gelucire44/14
In order to prepare the solid dispersion,there should be some selected solvents and they
should be chosen on the following basis:
1. Dissolve both the drug and the carrier
2. Toxic solvents should be avoided
3. Ethanol is a less toxic alternative
4.Water based systems preferable
5. Use of surfactants to create drug solutions but care should be taken.
Class I solvents (solvents to be avoided)
The class I solvent is used in the manufacture of the drug substances, excipients and drug
products because of their environmental effect.
Table  5: List of some class I solvents
Solvent Concentrationlimit(ppm) Concern
Benzene 2 Carcinogen
Carbon tetrachloride 4 Toxic and environmental
Hazards
1,2-dichloroethane 5 Toxic
1,1-dichloroethene 8 Toxic
1,1,1-trichloroethane 1500 Environmental hazards
Class II solvents(solvents to be limited)
Solvents that are in class II should be used in the limited basis because of their
inherent toxicity.
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Table 6: List of some class II solvents
Solvent PDE(mg/day) Concentration limit
Chlorobenzene 3.6 360
Chloroform 0.6 60
Cyclohexane 38.8 3880
1,2-dichloroethene 18.7 1870
Ethylene glycol 6.2 620
Methanol 30.0 3000
Pyridine 2.0 200
Toluene 8.9 890
Class III solvents(solvents with low toxic potential)
Class III solvents are regarded as the less toxic solvents and they have lower risk in the
human health. Class III includes no solvents known as a human hazard at level which is
normally accepted in the pharmaceuticals.(Boral et al,1995)
Class III solvents which should be limited by GMP or other quality based requirements
 Acetic acid heptane
 Acetone isobutyl acetate
 1-butanol isopropyl acetate
 2-butanol methyl acetate
 Butyl acetate 3-methyl-1-butanol
 Dimethylsulfoxidepentane
 Ethanol 1-pentanol
 Ethylacetate1-propanol
 Ethyl ethe2-propanol
 Formic acid    propyl acetate
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Table 7: Solid state solid dispersion
1. Eutectic mixture                                                          crystalline
2. Crystalline drug
Amorphous carrier
3. Amorphous drug
Amorphous carrier
2.4. Formulation of a poorly water soluble drugs Sirolimus in solid
dispersions to improve dissolution:
Sirolimus is the naturally water insoluble antibiotic that is produced by the Streptomyces
hygroscopicus bacterium. Sirolimus mainly act by the blocking the transcriptional activation
of cytokinesand then it inhibit the cytokine production.When bound to immunophilins,it is
bioactive.sirolimus is the potent immunosuppressnt  and mainly used in liver transplant and
to prevent therejection of kidney.Sometimes it is used in psoriasis,dermatitis.it also has anti
fungal and anti-neoplastic properties.(Shen et al,2007)
Two phase
solid system
Solid
dispersion
Solid state
single phase
solid system
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It has a high molecular weight,practically insoluble in water and doesn’t contain the
functional group that are ionizable in the ph range between 1 and 10.the oral bioavailability
of Sirolimus is approximately 15% in human transplant recipient.Due to extensive intestinal
and hepatic first-pass metabolism,there is large inter and intra-patient variability in the oral
bioavailability of sirolimus. (Buech et al,2007)
The bioavailability of Sirolimus is affected by other factors,such as drug
formulation,food,demographics,liver disease etc.The mean half life of Sirolimus is about 60
hours.There are number of approaches available to formulate poorly water soluble
compounds,which can be related to the well known Noyes-Whitney equation.(Amidon et
al,1995)
Dc/ dt=D*A*(Cs-Ct)/h*v
Where the dissolution rate (dc/dt) is determined by D
The diffusion layer thickness at the solid-liquid interface,h
The surface area of the drug,A
The volume of the dissolution media,V
The saturation solubility of the drug,Cs
The concentration at time t,Ct
This means the formulation increases the rate and the oral bioavailability include:via particle
size reduction increasing the surface area of drug,through improved wettability decreasing the
diffusion layer and increasing apparent solubility of the drug through the formation of
supersaturated drug solutions.
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2.4.1. Materials and experimental method:
Materials:
Sirolimus was received as a gift  fromBioconLtd.PEG 6000,poloxamer-188,mannitol,beta-
cyclodextrin,PVP K-30 were also received as gift samples.All other ingredients were of
laboratory grade.
Preliminary solubility studies of Sirolimus:
The solubility of Sirolimuswere performed according to the published method.Excess amount
of Sirolimus was added to 25 ml of aqueous solution of water soluble carriers like
urea,mannitol,PVP K-30,PEG-6000,beta-CD,Poloxamer-188 in the various ratio such as
1:1,1:2,1:3.1:4.For 24 hours the samples were taken at room temperature.Then the
suspensions were filtered through the Whatman filter paper.Then the solutions were
estimated for the sirolimus by UV-visible spectrophotometer at 278.0 nm.(Hguchi,1965)
2.4.2. Preparation of solid dispersions of Sirolimus:
Solid dispersion of sirolimus was prepared by the solvent evaporation method and the hot
melt method.The insoluble drug was dispersed into a molten carrier and cooled immediately
in the hot melt method.Ontheother,in the solvent evaporation method,the drug and the carrier
were dissolved in a common volatile solvent and then the solvent was evaporated to get solid
dispersions.
Hot melt method:
In this method the based on the preliminary solubility study,the carriers such as PEG
6000,Poloxamer-188 and mannitol were selected. The ratio was kept 1:1,1:2,1:3 and 1:4.at
about 60’C the carrier was first melted in the china dish and then the drug was dispersed in
the molten mixture with constant stirring.The dispersion was poured and cooled
immediately.it is a very tacky method.(Leuner,2000)
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Solvent evaporation method:
In this solvent evaporation method the drug and the carrier were dissolved in methanol with
constant stirring.Under low pressure to get the solid dispersion,the solution was evaporated.In
this method various carrier such as mannitol,PEG 6000 and Poloxamer-188 were used.The
ratio was kept 1:1,1:2,1:3 and 1:4.
Kneading technique:
In this method methanol is used as solvent and the water is also used.Small volume of
siroliumsbeta-cyclodextrin were triturated in mortar.The water –methanol ratio is 2:5 v/v.the
thick slurry was lneadedfor 45 minutes and then dried at 55’c in the hot air oven.It is dried
until it gets dried.
Differential scanning calorimetry:
Formulation of sirolimus and the thermal behavior were recorded using a differential
scanning calorimeter  with nitrogen flow rate of 40ml/min and a heating rate of 10’c/min at
20’c to 220’c.
X-ray diffraction studies:
Using Siemens (Germany)Kristallofex-d5000diffractometer the powder  x-ray diffraction
patterns were recorded.The samples were analyzed in the 20 angle range of 0’ to 60’.for the
pure drug and optimized formulation the diffraction patterns were recorded.(Jung et al,1999)
Dissolution testing:
Dissolution of sirolimus and the formulations were determined in simulated gastric
fluid.Dissolution testing was conducted in the temperature of 37+-1’c,500 mlusp VII 0.4%
SLS in distilled water.Amount equivalent to 2mg sirolimus were filledin size gelatin
capsules.Then the capsule was placed in the basket sinker of USP dissolution
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apparatus.Thenthe dissolution media was stirred at 100 rpm in the paddle method.Then the 1o
ml dissolution sample were collected at 10,20,30,45,60 and 120 minute respectively.After
that the solution was filtered.meanwhile an equal volume of fresh dissolution media was
maintained at the same temperature.(Verreck et al,2004)
2.4.3. Comparative studies of different drugs:
Preliminary solubility studies of Sirolimus:
The solubility of Sirolimus in water at 25’c is 2.6 ug/ml.under the preence of mannitol,PEG
6000,Urea,PVP K-30,HPMC 5 pcs and beta- CD , the phase diagram of the sirolimus was
taken out.The increasing of the correct amounts of dissolved drug was approximately linear
for Mannitol,PEG -6000,Poloxamer-188 and beta-cyclodextrin.(Amidon and Crison,1995)
FTIR studies:
Solid dispersion of sirolimus and the pure drug of sirolimuswesr researched for FTIR spectral
analysis.there was no any visible or non visible characteristic peaks for sirolimus in the solid
dispersion.Hence it described that there is no interaction between the pure drug and the
carrier used.
Dissolution testing:
The data from dissolution testing shows rapid dissolution of sirolimus from the solid
dispersion and the solid complex when compared with the pure drug and the physical
mixture.As the proportion of the poloxamer-188 and Mannitol carrier in the solid dispersion
becomes higher the cumulative percentage of sirolimus.Solid dispersion prepared from
solvent evaporation method with PEG -6000 in the ratio of 1:1 increased release with t50% of
60 minutes and achieved the highest amount of release of 99.45%
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2.5. Enhancement of dissolution of Fenofibrate by solid dispersion
technique:
Fenofibrate is a lipid lowering drug used in the treatment of hyperlipidemia, which is not
soluble in water and lower absorption in gastric fluid. In order to increase the solubility and
oral absorption of the drug in gastric fluid and to increase its dissolution rate solid dispersions
and Lyophilization of dispersion is designed and evaluated. Solid dispersions of Fenofibrate
were made using PEG 6000, Poloxamer 407 and a mixture of PEG 6000 and Poloxamer
407(1:1 mixture). The result of melt and solvent methods of making of solid dispersion on
dissolution behavior was also invented.Dissolution studies showed a significant raise in
dissolution of Fenofibrate when dispersed in PEG6000 and Poloxamer 407. Physical mixtures
having PEG and Poloxamer 407 also indicated great dissolution of Fenofibrate as compared
with that of pure drug, indicating the solubilizing effect of PEG6000 and Poloxamer 407.
Solid dispersions having Fenofibrate /Poloxamer 407, 1: 8, showed a 14-fold increase in
dissolution after 60 min (D60) (Y.E and Wilken,1980) and another dispersion having
Fenofibrate /PEG 6000, 1:10, showed an 8-folds. The dispersion having  six parts of the PEG
6000: Poloxamer 407 mixture (PEG 4000/PEG 6000, 1:1 mixture) showed a 12-fold raise in
D60 as compared with pure drug. When multi-carrier solid dispersion having  six parts of
mixture was prepared by the solvent method, the D60 value was about 2-fold that of the same
dispersion made by the melt process. The dissolution of lyophilized solid dispersions further
raised  the dissolution of Fenofibratespecificly.(Sugimoto et al,1998)
2.5.1. Experimental methods:
Apparatus and chemicals :
Fenofibrate (99% purity) was obtained from Aurobindo pharmaceuticals, India. MCC,
pregelatinized starch was obtained from Kemphasol, Bombay. PEG 6000 was purchased
from Merck. Other excipients used were of analytical grade. (Hncock and Zografi,199
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2.5.2. Preparation of solid dispersion of Fenofibrate:
Solvent Evaporation method using fluid-bed coating technique:
The Fenofibrate was dispersed in hydrophilic polymers like PEG 6000.Surfactants like
PEG400 or Miglyol or Cremophore EL are needed to disperse Fenofibrate in polymer.Then
this dispersion was dissolved with the help of  IPA& DCM solvents.The solid solution of
Fenofibrate polymer was coated onto inert bed of Sugar spheres or Lactose monohydrate
using Fluid-bed coater granulater.Therefore solvent will be evaporated leaving a
Fenofibrate-polymer coat surrounding the inert carrier. The dry mass will be achieved in
granular state which was passed through 30 mesh (ACTM No. 30) and composition of solid
dispersion.
Differential scanning calorimetry (DSC) analysis:
Thermal properties of Fenofibrate, polymer and solid dispersion were invented by using
differential scanning calorimeter thermal analysis controller with an intracooler-2 cooling.
About 3 to 5 mg of product was taken  in perforated aluminum sealed 50-μ
l pans, and the heat runs for each sample was set from 40°C to 250°C at
10°C/min,(Munoz et al,1994) under an inert surroundings with the help of nitrogen.The
apparatus was calibrated using pure metals like indium with known melting points and heat
of fusion.
Dissolution studies :
Dissolution studies were taken in phosphate buffer (pH 7.2, 900 ml) at 37 ± 0.5 °C, using
USP apparatus with a paddle rotating at 75 rpm.The samples equivalent to 120 mg
fenofibrate, were concerned to dissolution. At fixed time difference samples (5 ml) were
withdrawn and equal amount of fresh dissolution medium was added. Withdrawn samples
were filtered through 0.45 μm membrane filter, and spectrophotometrically assayed for drug
content at
287.4 nm wavelengths with the help of  a UV-VIS spectrophotometer.
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Stability studies :
Stability studies were taken out by keeping the samples in screw cap vials in stability
chambers at 25 ± 2°C and 60 ± 5 % relative humidity (RH). Samples were taken regularly
and researched for drug content and dissolution studies until 6 months. All the data are
collected from the stability study were analyzed for significant differences by one-way
Analysis.
2.5.3.Comparative studies of different drugs
Various Fenofibrate solid dispersions were made by using PEG-400,6000,
MCC,pregelatinized starch in the mixture and individually, as taken by solvent evaporation
technique to higher the solubility as well as dissolution of poorly aqueous soluble drug
Fenofibrate. The DSC thermograms of pure fenofibrate and fenofibrate solid dispersion by
using PEG-600.(McKenzie,1976)
2.6. Enhancement of dissolution of Furosemide by solid dispersion
technique:
2.6.1. Materials and methods:
Materials:
The samples of FUR, PEG 6000, and PVP K30 (average molecular weights of 6000 and
50000, respectively ) were generous gifts from Maan Pharmaceuticals Ltd. (Mehsana, India)
and were used without further purification . Directly compressible lactose, colloidal silicon
dioxide, and magnesium stearate were produced from S.D Fine-Chem Ltd,  Mumbai. All
chemicals and solvents were of analytical reagent grade that had been used in the study.
Throughout the work freshly distilled water was used. (Habib and Attia,1985)
P a g e 38 | 38
Phase solubility study:
Phase-solubility research have been performed in line with the method noted through Higuchi
and Connors (18). FUR, in amounts that exceeded its solubility,  have been transferred to
screw-capped vials made up of 30 mL aqueous PEG 6000 or maybe PVP K30 alternatives
regarding diverse concentrations of mit (0, 1, 5, and 10%). The contents have been stirred
while on an electromagnetic stirrer (Remi, India) at 25 °C and 37 °C for 72 h and 300 rpm.
This particular duration had been screened to be enough to reach equilibrium, after which  no
advancement in solubility was noticed. Immediately after hitting equilibrium, biological
samples have been television through a 0. 22-µm membrane layer filtration system, very well
diluted with 0. 1 And NaOH, and analyzed for drug content at the λmax regarding 274 nm
(17) by using a spectrophotometer (Shimazdu-1601, UV–vis spectrophotometer, Shimadzu
Corp, Kyoto, Japan). Most assays have been performed in triplicate.(Patel,2007)
2.6.2. Preparation of Solid Dispersion and Physical Mixture:
Solid Dispersions Served by Solvent Evaporation SDs involving of SDs within PEG 6000 as
well as PVP K30 that contain distinct pounds rates (1: 1, 1: 5, 1: 10 in addition to denoted
since SEPEG or SEPVP 1/1, 1/5, 1/10, respectively) were being made by the solvent
technique (19) as follows.Toa answer involving FUR within ethanol (10 mg/25 mL), the right
volume of PEG 6000 or PVP K30 seemed to be included. Solvent seemed to be evaporated
under diminished  pressure at 40 °C, and the caused deposit seemed to be dried out
underneath vacuum cleaner intended for 3h, stored in a desiccator at least overnight, ground
in a mortar, and passed through a 100 sieve.(Franco et al,2001)
Solid Dispersions Prepared by Melting of the Carrier:
Four SD preparations containing different weight ratios of FUR in PEG 6000 (1:1, 1:5, 1:10
and denoted as MEPEG 1/1, 1/5, 1/10, respectively) were prepared by the melting method
(20). FUR was added to the melted PEG 6000 at 75 °C, and the resulting homogeneous
preparation was rapidly cooled in a freezing mixture of ice and sodium chloride, and stored in
a desiccator for 24 h. Subsequently, the dispersion was ground in a mortar and sieved through
a 100 sieve.
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Physical Mixtures
Physical mixtures (PMs) having the same weight ratios, as described in the previous two
methods, were prepared by thoroughly mixing appropriate amounts of FUR and PEG 6000 or
PVP K30 in a mortar until a homogeneous mixture was obtained. The resulting mixtures
were sieved through a #120 sieve and denoted as PMPVP or PMPEG, respectively.
Characterization of Solid Dispersion:
Infrared (IR) Spectroscopic Analysis:
FTIR spectra of moisture-free powdered samples of FUR and its PMs and SDs with PEG
6000 and PVP K30 were obtained using a spectrophotometer (FTIR-8300, Shimadzu Co.,
Kyoto, Japan) by potassium bromide (KBr) pellet method. The scanning range was 750–4000
cm−1, and the resolution was 1 cm−1.(Van den Mooter,1998)
Powder X-ray Diffraction (PXRD) Analysis:
The physical state of FUR in the various preparations was evaluated by powder X-ray
diffraction study. Powder X-ray diffraction patterns of all samples were determined using a
Phillips PW 3710 scanner, IW 1830 generator with a CuK α anode at 40 kV and 30 mA, and
a scan rate of 1° min−1 from 2θ range 1 to 40°.
Differential Scanning Calorimetry (DSC) Analysis:
DSC tests of most powdered biological samples were registered utilizing Shimadzu DSC-60
using TDA tendency series software program. All biological samples were weighed (8–10
mg) along with warmed up in a scanning rate associated with 10 °C/min under dry nitrogen
flow (100 mL/min) between 50 and 300 °C. Aluminum  pans  along with lids were used for
almost all biological samples. Pure  water along with indium seeing that primary regular were
used to calibrate the DSC temperature scale along with enthalpic reaction.
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Wettability and Dissolution Studies :
A new wettability research was executed employing open up tubes comprising FUR and its
PMs as well as SDs together with PEG 6000 as well as PVP K30; these were placed using
lower capillary ends dropped into hued normal water (0. 01% eosin with water). The upward
migration of the colored front was registered as a function of time (21). . Dissolution research
involving FUR with powdered ingredients type and its PMs as well as SDs together with
PEG 6000 as well as PVP K30 were executed to evaluate in vitro drug release profile.
Dissolution research were executed employing USP Apparatus 2 together with 500 mL
dissolution medium (demineralized normal water comprising 0. 25% [w/v] involving salt
lauryl sulfate [SLS]) at 37 ± 0. 5 °C (Teresa and Victoria,2002) as well as 50 rpm intended
for 4h. Samples of pure FUR and PMs and SDs equivalent to 20 mg of the drug were added
to the dissolution medium. At fixed time intervals, 5-mL aliquots were withdrawn, filtered
through a 0.22-µm membrane filter, suitably diluted, and assayed for FUR content by
measuring the absorbance at 274 nm using a spectropho- tometer. Equal volume of fresh
medium prewarmed at the same temperature was replaced in the dissolution medium after
each sampling to maintain constant volume throughout the test. Each test was performed in
triplicate, and release curves were plotted using calculated mean values of cumulative drug
release. Similarity factor (f2) and mean dissolution time (MDT) values were calculated to
compare the extent of improvement in the dissolution rate of FUR from different samples.
Preliminary tests demonstrated that there was no change in the λmax of FUR due to the
presence of PEG 6000 or PVP K30 dissolved in the dissolution medium.
Formulation Studies:
Formulation excipients were selected on the basis of preliminary tests, which demonstrated
no interference of these excipients with the λmax of FUR. Tablets containing 20 mg of FUR
were made by direct compression using different formulation excipients such as directly
compressible lactose, colloidal silicon dioxide, and magnesium stearate. Tablets containing
SDs equivalent to 20 mg FUR were made similarly. The blend was compressed on an eight-
station single rotary machine (Cadmach, India) using round-shaped, flat punches to obtain
tablets of 3–6 kg/cm2 hardness and 3.8–4.0 mm thickness. For the assay, three tablets were
crushed, and a blend equivalent to 10 mg of FUR was weighed and dissolved in dissolution
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medium. The release profile of drug from tablets was studied in triplicate using the same
dissolution media, conditions, and procedure as described for in vitro dissolution studies.
2.6.3.Comparative studies of different drugs
Phase-Solubility Study The solubility of FUR in water at 25 °C is 10 µg/mL; therefore, FUR
can be considered to be a water-insoluble drug. The phase solubility curve of FUR in the
presence of PEG and PVP at 25 and 37 °C . (For ease in discussion, hereafter, PEG 6000 and
PVP K30 are abbreviated as PEG and PVP, respectively). From this curve, it can be seen that
the apparent solubility of FUR increased with increasing temperature and carrier
concentrations. At the highest polymer concentration (10% w/w), the solubility increased
approximately 27-fold and 23-fold for PEG and PVP, respectively, at 37 °C. The same
tendency was observed at 25 °C. An indication of the process of transfer of FUR from pure
water to aqueous solution of PEG or PVP was obtained from the values of Gibbs free energy
change (25). The Gibbs free energy of transfer (∆Gtr°) of FUR from pure water to aqueous
solutions of SDs was calculated using the following equation:
Equation:
whereSc/So is the ratio of molar solubility of FUR in aqueous solution of PEG or PVP to that
of pure water. The enthalpy of transfer (∆Ht°) can be calculated from a modification of the
van’t Hoff equation: ∆HRSS Tt coo =− () ( ) dln d1 [4] The obtained values of ∆Gtr°, ∆Ht°,
and apparent stability constants (Ka). The ∆Gtr° values show whether the reaction condition
is favorable or unfavorable for drug solubilization in the aqueous carrier solution. Negative
∆Gtr° values indicate favorable conditions. ∆Gtr° and ∆Ht° values were all negative for both
polymers at various concentrations, indicating the spontaneous nature of FUR solubilization,
and decreased with an increase in PEG or PVP concentration, demonstrating that the reaction
became more favorable as the concentration of PEG or PVP increased. These values also
indicated that the extent of improvement in solubility was more with PEG as compared with
PVP.
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Characterization of SDs:
Fourier Transform Infrared (FTIR) Spectroscopic Analysis:
FTIR has been used to assess the interaction between carrier and guest molecules in the solid
state. In the SD preparations, there is a peak band shift in the absorption spectrum of the
guest. However, some of the changes are very subtle requiring careful interpretation of the
spectrum.
The spectrum of pure FUR presented characteristic peaks at 3340 cm−1 (NH2 stretching
vibration of Ar-NHCH2), 3260 cm−1 (stretching vibration of SO2NH2), 1665 cm−1
(bending vibration of amino group), 1560 cm−1 (asymmetric stretching vibration of the
carboxyl group), and 1318 cm−1 (asymmetric stretching vibration of the sulfonyl group).
Important vibrations detected in the spectrum of PEG are the C–H stretching at 2890 cm−1
and the C–O (ether) stretching at 1125 cm−1. The spectrum of PVP showed important bands
at 2925 cm−1 (C–H stretch) and 1652 cm−1 (C=O). A very broad band was also visible at
3300 cm−1, which was attributed to the presence of water confirming the broad endotherm
detected in the DSC experiments.
The spectra of PMPEG 1/10 and PMPVP 1/10 can be simply regarded as the superposition of
those of FUR and PEG or PVP. No difference was seen in the position of the absorption
bands of FUR and PEG or PVP.
In the spectra of SEPEG 1/10, MEPEG 1/10, and SEPVP 1/10, the characteristic peaks of
PEG or PVP were present at almost the same positions, whereas peaks due to FUR were
absent indicating trapping of FUR inside the PEG or PVP matrix. Moreover, all the spectra
showed no peaks other than those assigned to FUR, PEG, and PVP, which indicates the
absence of any well-defined chemical interactions. Although hydrogen bonding between the
hydrogen atom of the OH of the drug and oxygen atom in PEG or PVP could be expected,
this was not demonstrated.
The presence of numerous distinct peaks in the PXRD spectrum indicate that FUR was
present as a crystalline material with major characteristic diffraction peaks appearing at a
diffraction angle of 2θ at 5.95, 11.98, 14.11, 18.05, 18.90, 20.36, 21.28, 22.82, 24.73, 27.48,
and 29.17. PEG also exhibited a distinct pattern with diffraction peaks at 2θ at 15.00, 18.75,
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23.15, 26.60, and 29.35, but the spectrum of PVP was characterized by the complete absence
of any diffraction peak, which is characteristic of an amorphous compound.
The diffraction patterns of all the samples of SDs show peaks due to PEG or similar to PVP
and an absence of major diffraction peaks corresponding to FUR, with most of the diffraction
indicating FUR was present as amorphous material inside the PEG or PVP matrix. Moreover,
no peaks other than those that could be assigned to pure FUR and PEG or PVP were detected
in the SEPEG 1/10, MEPEG 1/10, and SEPVP 1/10, indicating no chemical interaction in the
solid state between the two entities. In the case of physical mixing, diffractograms of PMPEG
1/10 showed more resemblance to PEG, whereas diffractograms of PMPVP 1/10 showed
resemblance to FUR due to presence of free drug.
Differential Scanning Calorimetry (DSC) Studies:
DSC enables the quantitative detection of all processes in which energy is required or
produced (i.e., endothermic or exothermic phase transformations). The thermal behavior of
the prepared solid dispersions of FUR with PEG and PVP was studied by DSC.  The FUR
showed a melting peak at 225 °C with an enthalpy of fusion (∆H) of 302.22 mJ/g (26). The
DSC scan of PVP showed a broad endotherm ranging from 80 to 120 °C due to the presence
of residual moisture in PVP, whereas PEG showed a single sharp endotherm at 58 °C due to
melting. DSC thermograms of PMPEG 1/10 and PMPVP 1/10 showed the melting peak of
the drug at 225 °C, a sharp endothermic peak at 58 °C due to melting of PEG, and the broad
endotherm due to the presence of water ranging from 90 to 110 °C in PVP. The DSC scans of
SEPEG 1/10 and MEPEG 1/10 showed only one peak at 58 °C due to melting point of PEG,
and the scan of SEPVP 1/10 showed one peak at 90–110 °C due to loss of water from PVP.
All samples of SDs showed complete absence of drug peak at 225 °C. This complete absence
of the FUR peak indicates that FUR is amorphous or is in a solid solution inside the PEG and
PVP matrix. This type of interaction was also observed in the FTIR and PXRD studies.
Wettability and Dissolution Studies:
The wettability regarding FUR has been appreciably increased simply by organizing it's solid
dispersions having PEG and PVP (Figure 5). The best progress regarding wettability in water
P a g e 44 | 44
has been witnessed having SEPEG 1/10 and SEPVP 1/10 (58. 7% and 49. 9%, respectively
after 60 min). A large progress inside the wettability regarding FUR has been furthermore
observed in PMPEG 1/10 and PMPVP 1/10 as compared having pure FUR (20%) after 60
min.
It really is typically accepted which dissolution advertising are not absolutely adviser
regarding gastrointestinal (GI) disorders yet it is proposed in guidelines that a good method
will employ a dissolution medium  that is certainly physiologically purposeful or perhaps
directly mimics in vivo disorders (27). It is often suggested which such as surface-active
providers in dissolution advertising is significant with regard to inadequately soluble
materials, because the lack of any area strain reducing realtor would lead to lesser wetting
and in vitro dissolution rates which might be not necessarily adviser regarding in vivo
conditions (27). It has been suggested that including surface-active agents in dissolution
media is important for poorly soluble compounds, because the lack of a surface tension
lowering agent would result in poorer wetting and in vitro dissolution rates that are not
representative of in vivo rates (28). The FDA has permitted the use of surfactants in media
for conducting dissolution studies of poorly soluble compounds (29).
Dissolution of pure FUR and all other prepared systems (SDs and PMs) were carried out in
demineralized water containing 0.25% (w/v) SLS. DP30 min values (percent drug dissolved
within 30 min), t50% (time to dissolve 50% drug), and mean dissolution time (MDT) values
for different samples.In vitro dissolution profiles of pure FUR, its PM and SDs with PEG and
PVP over a period of 4.
It is evident that the dissolution rate of pure FUR is very low (DP30 min 7.6%, t50% >> 4 h,
and MDT of 58.3 min at 4 h). SDs of FUR with PEG and PVP significantly enhance the
dissolution rate of FUR (80–95%, respectively) within 4 h as compared with PM as well as
pure FUR. PMs with PEG and PVP also improved the dissolution rate of FUR. The highest
improvement was obtained in SDs prepared with PEG by solvent evaporation techniques.
SEPEG 1/10 (97%) has a higher dissolution rate as compared with SEPVP 1/10 (88%) at the
end of 4 hrs.
The obtained values of MDT for all samples are presented in Table 2. The MDT of pure
FUR is very high (58.3 min). This value decreased to a greater extent after preparing its SDs
and PM with PEG and PVP. SEPEG 1/10 showed the lowest MDT (20.2 min). MDT values
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of SDs prepared with PEG were lower than that with PVP. The same relationship was also
observed with PM prepared with PEG and PVP also.
Comparisons between the release profiles of FUR from different samples were made by
similarity factor f2. From this table, it is evident that the release profile of FUR from all the
samples (i.e., SDs and PMs of PEG and PVP) and from pure FUR was dissimilar since f2
values for all these comparisons were less than 50. Release profiles of FUR from SEPEG and
MEPEG at different concentrations were similar. Release of FUR from SDs with PEG and
PVP were also significantly different from PMs with PEG and PVP at different concentration
levels.
Formulation Studies:
The physical properties of all samples were studied to judge tabletting ability. In general,
compressibility index values up to 15% and an angle of repose between 25 and 30 results in
good to excellent flow properties (30). Percentage compressibility and the angle of repose of
samples are. These values indicate good compressibility and flow properties, making these
samples suitable for tableting.
Release profiles of FUR from conventional tablets containing FUR (without PEG or PVP)
and tablets containing SDs and PMs of FUR with PEG or PVP Are shown.Release of FUR
from tablets containing SDs with PVP or PEG was faster and greater as compared with
conventional tablets containing FUR. This confirmed the advantage of improved aqueous
solubility of FUR in its SD form, which can be formulated as tablets with better dissolution
characteristics.
DP30min, t50%, and MDT values for release of FUR from tablets prepared using different
samples. DP30min values were higher for tablets prepared using SDs and PMs as compared
with those of conventional tablets containing only FUR (2.9), whereas t50% and MDT values
of FUR from tablets containing SDs and PMs were significantly lower than those of
conventional tablets containing only FUR and no PEG or PVP (76.0 min and >4 h,
respectively).
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Chapter-3
DISCUSSION
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3. DISCUSSION
After studying about the various method of solid dispersion, we can say that there are some
methods which are followed by individual drugs. In recent days these three methods are
widely used in these following drugs.
1. Physical mixing method
2. Solid evaporation method
3. Melting method
The drugs that follow these three methods are-
 .Fenofibrate
 .Furosemide
 .Sirolimus
 .Lurasidone HCL
 .Terbinafine hydrochloride
 .Indomethacin
 .Simvastatin
 .Meloxicam
 .Gliclazide
 .Lornoxicam
 .Diacerein
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From this Pi chart we can say that, 50% of the drugs are followed by physical mixing method
30% by solvent evaporation method and remaining 20% by the melting method.
Lurasidone HCl,Terbinafine,Indomethacin,Simvastatin,Meloxicam,Gliclazide,Diacerein are
dispersed by using physical mixing method.
In this kneading method, transporter is permeated with water and transformed to paste. Drug
is then added and kneaded for particular time. The kneaded amalgamation is then dried and
passed  through sieve if obligatory.
Furosemide,Sirolimus,Lurasidone HCl,Terbinafine hydrochloride,Diacerein are dispersed by
solvent evaporation method. In this solid dispersion procedure, both drug and carrier are
dissolved in organic solvent. After whole dissolution, the solvent is evaporated.The solid
mass is ground, sieved and dried. Ex. Solid dispersion of furosemide with eudragits was
organized by solvent evaporation method (Rasenack et al., 2003).
And lastly,Fenofibrate,Furosemide,Sirolimus,Terbinafine,Lornoxicam are dispersed by using
the melt method. Drug and carrier are assorted using mortar and pestle. To accomplish a
homogenous distribution the assortment is frenzied at or beyond the melting point of all the
Solvent
Evaporation
Method
30%
Melting Method
20%
Methodology of various Drugs
Physical Mixing
Method
50%
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components. It is then cooled to attain a congealed mass. It is crushed and sieved.
Ex.albendazole and urea solid dispersion was prepared by this method (Kalaiselvan et al.,
2006).
Physical mixing method is widely used over all other methods because of its prominent
temperature for about one minute.It can reduce maximum temperature and result in less
decomposition of drugs. This method is mostly used over other methods because of their low
cost. This method is environment friendly.
Researchers have been conducting physical mixing method research for several decades.
Early articles on the application of such designs have referred to them as multi-method,
integrated, hybrid, combined, and mixed methodology research (Creswell and Plano Clark
2007).
From our pichart we can describe that about 30% of drugs are dispersed by using the solvent
evaporation method and the main advantage of this method is thermal decomposition of
drugs orcarriers which can be prevented by relatively low temperature that is required for the
evaporation of solvent. Beside that there are some multiple disadvantages of this method such
as-expensive,ecological,environmental problems and difficult to find a common and
removable solvent.(Nakamura A,1965)
Finally there is limited use of the melting method because this method can only be applied
when drugs and the matrix are compatible and mix well at the heating temperature. Otherwise
it results in homogenous solid dispersion.And because of this phase separation may
occour.(Damian et al,2002)
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Conclusion:
Solid dispersion has great possible both for increasing the bioavailability of drug and
mounting controlled release preparations. in regard to manufacturing considerations the
problem of total solvent removal in dispersions prepared by solvent evaporation way need to
be addressed (Singh et al,1966). With particle-coating utensils new commercially available,
this course has a promising future. The problem of volatility of the supersaturated state upon
dissolution, which results in a stable form, has been dealt with by addition of a retarding
agent. Methylcellulose used as a retarding agent in dispersions of indomethacin and
flufenamic acid in PVP (SjokvistE,1992). Proscribed release formulations of acetaminophen,
aminopyrine, chlorpheniramine  maleate and salicylic acid that use eudragit RS  as water
insoluble carrier organized by solvent method, have been reported. Valuable preliminary
studies of the use of solid dispersions to provide sustained release or controlled release of
drugs have been reported.(Slade L,1991)
Solid dispersion can boost dissolution rate of drugs with poor water solubility of these
systems requirements consideration. Physical and chemical stability of both the drug and the
transporterin a solid dispersion are major developmental issues,as exemplified by the recent
withdrawal of ritonavir capsules from the market, So future research desires to be directed to
address diverse stability issues. solid dispersions can progress their stability and recital by
increasing drug-polymer solubility, amorphous fraction, particle wettability and particle
porosity. Moreover, new, optimized manufacturing techniques that are easily scalable are also
coming out of academic and industrial research. Further studies on scale up and validation of
the process will essential.
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